154 Stock Chart & Stats
€13.28
-€0.18(-1.35%)
At close: 4:00 PM EDT
€13.28
-€0.18(-1.35%)
Day’s Range― - ―
52-Week Range€11.02 - €13.88
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€737.81M
Enterprise Value€371.44
Total Cash (Recent Filing)€501.12M
Total Debt (Recent Filing)€4.45M
Price to Earnings (P/E)12.0
Beta0.44
Next Earnings
Oct 28, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding57,480,770
10 Day Avg. Volume11
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.39
Price to Sales (P/S)2.56
P/FCF Ratio11.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.81Price Target Upside4.01% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)1.12
Revenue Forecast (FY)€320.15M
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance SheetNear-zero leverage and a multi-hundred‑million dollar cash/marketable securities position give InMode durable financial resilience. This lowers refinancing and solvency risk, supports investment or buybacks, and cushions the business through demand cycles over the next several quarters.
High Margins And Cash ConversionSustained high gross margins and healthy net margins reflect differentiated, high‑value device sales and recurring consumables. Coupled with operating cash flow that exceeds net income, this supports durable cash generation and reinvestment capacity even as top‑line growth moderates.
Product Portfolio ExpansionOngoing platform introductions and an expanding procedure set broaden addressable markets and strengthen consumable annuity streams. FDA pipeline progress (Erbium) and cross‑specialty applications help diversify revenue and reduce reliance on any single geography or treatment over time.
Bears Say
Margin Compression TrendMaterial margin erosion driven by product mix, platform introductions and higher commission/marketing spend suggests pressure on structural profitability. If new platforms and higher opex persist, sustained margin compression could reduce free cash flow and shareholder return potential over multiple quarters.
Revenue DecelerationA shift from rapid growth to flat/declining top line weakens operating leverage and constrains long‑term cash‑flow growth. Persistent slower demand would limit benefits from the installed base and consumables tail, pressuring reinvestment and returns unless new products or regions restore sustained revenue expansion.
Governance And Takeover DistractionsActive takeover bids, shareholder disputes and court filings create governance uncertainty and can divert management and board focus from commercial execution. Prolonged review or litigation risks delay strategic decisions, impede M&A or integration plans, and may depress long‑term operational momentum and investor confidence.
InMode News
154 FAQ
What was InMode’s price range in the past 12 months?
InMode lowest stock price was €11.02 and its highest was €13.88 in the past 12 months.
What is InMode’s market cap?
InMode’s market cap is €737.81M.
When is InMode’s upcoming earnings report date?
InMode’s upcoming earnings report date is Oct 28, 2026 which is in 68 days.
How were InMode’s earnings last quarter?
InMode released its earnings results on Aug 05, 2026. The company reported €0.303 earnings per share for the quarter, beating the consensus estimate of €0.3 by €0.003.
Is InMode overvalued?
According to Wall Street analysts InMode’s price is currently Undervalued.
Does InMode pay dividends?
InMode does not currently pay dividends.
What is InMode’s EPS estimate?
InMode’s EPS estimate is 0.28.
How many shares outstanding does InMode have?
InMode has 57,480,770 shares outstanding.
What happened to InMode’s price movement after its last earnings report?
InMode reported an EPS of €0.303 in its last earnings report, beating expectations of €0.3. Following the earnings report the stock price went down -0.683%.
Which hedge fund is a major shareholder of InMode?
Currently, no hedge funds are holding shares in DE:154
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€13.81 (4.01% Upside)
€13.81 (4.01% Upside)
Blogger Sentiment
Bullish
DE:154 Sentiment 75%
Sector Average 61%
Sector Average 61%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.69%
Trailing 12-Months
Company Description
InMode
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
154 Company Deck
154 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.View all DE:154 earnings summaries154 Stock 12 Month Forecast
Average Price Target
€13.81
▲(4.01% Upside)
Technical Analysis
Orthofix Medical
―
AxoGen
―
Establishment Labs Holdings
―
SS Innovations International
―
Bioventus
―